Category: Drug Development and Approvals

Lung Cancer Updates from 2017 ASCO Annual Meeting

Each year in early June the American Society for Clinical Oncology holds its Annual Meeting (called simply “ASCO”) in Chicago. The theme for the 2017 meeting was “Making a Difference in Cancer Care WITH YOU.” Over 39,000 cancer researchers, clinicians, patient advocates, and industry representatives from around the world gathered to discuss the latest scientific… Read More

Posted by Janet Freeman-Daily on July 26th, 2017

How Corporations Really Know What’s Good for the Patient

Richard Goodfellow of CEO of biotech Scancell Talks about how patient advocacy groups are central to understanding patient needs. He emphasizes that working with advocacy groups are an innovative and productive way of ensuring patients are at the forefront of everything they do. Click here to read the full commentary

Posted by Richard Goodfellow on July 26th, 2017

FDA Approves KEYTRUDA as First-Line Combination Therapy, Irrespective of PD-L1 Expression

Congratulations, Merck, for the approval of KEYTRUDA® in first-line combo therapy irrespective of PD-1 expression. The improved responses seen with KEYTRUDA® plus pemetrexed/carboplatin regimen are significant, and highlight the importance of finding new approaches that address the unmet needs of patients with metastatic nonsquamous non-small cell lung cancer. Read the full press release here

Posted by ALCF Staff on May 10th, 2017

Do you know a ROS1-fusion positive cancer patient?

In May, 2016, the Bonnie J. Addario Lung Cancer Foundation launched the Global ROS1 Initiative, in partnership with cancer patients whose tumors are driven by ROS1 gene fusions. These ROS1 gene fusions are abnormal changes in cells that drive the growth and spread of several different cancer types such as non-small cell lung, gastric, ovarian,… Read More

Posted by Dr. Guneet Walia on February 23rd, 2017

Liquid Biopsy Test Approved by the FDA for EGFR+ Lung Cancer

On June 1, 2016 the US Food and Drug Administration (FDA) approved the first ever blood test to aid clinical decision making for targeted therapies for lung cancer. This blood test, a companion diagnostic called Cobas EGFR Mutation Test v2, allows the detection of mutations in the EGFR (Epidermal Growth Factor Receptor) gene, such as… Read More

Posted by Dr. Guneet Walia on September 29th, 2016

Invictan-2 Clinical Trial for Nonsquamous NSCLC

A new clinical trial from Boehringer Ingelheim will be studying the safety and efficacy of a new drug call INVICTAN-2. The drug is similar to the biologic medication Avastin (bevacizumab) which is already approved as a treatment for nonsquamous non-small cell lung cancer. In order to be eligible to participate, you must meet the following… Read More

Posted by ALCF Staff on August 31st, 2016

Lung Cancer Updates from ASCO 2016

Download PDF of this post What is ASCO? ASCO is the American Society of Clinical Oncology that has an annual meeting each year where key research and clinical medicine highlights are presented by cancer researchers & clinicians to the global community. This was the 52nd Annual Meeting of the American Society of Clinical Oncology, held… Read More

Posted by Dr. Guneet Walia on July 20th, 2016

New Clinical Trial Available for ALK+ NSCLC patients- XALT2

If you have non-small cell lung cancer (NSCLC), you may be interested in learning more about a clinical research study opportunity. Non-small cell lung cancer (NSCLC) is one of two types of lung cancer (the other is small cell lung cancer). Most lung cancers are NSCLC. Of the people who have NSCLC, only 3 percent… Read More

Posted by Danielle Hicks on April 1st, 2016

New Clinical Trial For Patients No Longer Benefitting from Standard Therapy, or For Whom No Standard Therapy is Available

This Monday, the American Society of Clinical Oncology (ASCO) launched its first ever clinical trial that has been designed with a unique format and allows patients with advanced solid tumor (including lung cancer), multiple myeloma, or B cell non-Hodgkin lymphoma who are no longer benefitting from standard anti-cancer treatments, or for whom no acceptable standard… Read More

Posted by Dr. Guneet Walia on March 23rd, 2016

FDA Approves Crizotinib for first-line treatment of ROS1+ patients

The US Food and Drug Administration (FDA) today granted approval to Crizotinib (Xalkori) for the treatment of patients with ROS1-rearranged metastatic non-small cell lung cancer (NSCLC). Crizotinib was approved in 2011 for the treatment of patients with ALK-rearrangement positive NSCLC. What are ROS1 Fusions: ROS1 gene fusions occur when the ROS1 gene abnormally fuses with… Read More

Posted by Dr. Guneet Walia on March 11th, 2016